Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation

British Journal of Pharmacology

Volumn 147, Issue 6, 2006, Pages 612-621

  Gardiner, Sheila M ^a   March, Julie E ^a   Kemp, Philip A ^a   Maguire, Janet J ^b   Kuc, Rhoda E ^b   Davenport, Anthony P ^b   Bennett, Terence ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Haemodynamics; Rats; Urotensin II; UT receptors

Indexed keywords

INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROPRANOLOL; PROSTAGLANDIN SYNTHASE; RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UROTENSIN; UROTENSIN II RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DOPPLER FLOWMETRY; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENE LOCATION; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; IMMUNOREACTIVITY; INFUSION; INOTROPISM; INTRAVASCULAR CATHETER; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; TACHYCARDIA; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; HEMODYNAMIC PROCESSES; HINDLIMB; INDOMETHACIN; INFUSIONS, INTRAVENOUS; MALE; MUSCLE, SKELETAL; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; REGIONAL BLOOD FLOW; UROTENSINS; VASODILATION;

EID: 33645106688     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706503     Document Type: Article

References (26)

1. ABDELRAHMAN, A.M. & PANG, C.C.Y. (2002). Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci., 71, 819-825.
2. AFFOLTER, J.T., NEWBY, D.E., WILKINSON, I.B., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. J. Clin. Pharmacol., 54, 617-621.
3. AMES, R.S., SARAU, H.M., CHAMBERS, J.K., WILLETTE, R.N., AIYAR, N.V., ROMANIC, A.M., LOUDEN, C.S., FOLEY, J.J., SAUERMEICH, C.F., COATNEY, R.W., AO, Z., DISA, J., HOLMES, S.D., STADEL, J.M., MARTIN, J.D., LIU, W.-S., GLOVER, G.I., WILSON, S., MCNULTY, D.E., ELLIS, C.E., ELSHOURBAGY, N.A., SHABON, U., TRILL, J.J., HAY, D.W.P., OHLSTEIN, E.H., BERGSMA, D.J. & DOUGLAS, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
4. BOTTRILL, F.E., DOUGLAS, S.A., HILEY, C.R. & WHITE, R. (2000). Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol., 130, 1865-1870.
5. CLIFFORD, P.S. & HELLSTEN, Y. (2004). Vasodilatory mechanisms in contracting skeletal muscle. J. Appl. Physiol., 97, 393-403.
6. CLOZEL, M., BINKERT, C., BIRKER-ROBACZEWSKA, M., BOUKHADRA, C., DING, S.-S., FISCHLI, W., HESS, P., MATHYS, B., MORRISON, K., MÜLLER, C., MÜLLER, C., NAYLER, O., QUI, C., REY, M., SCHERZ, M.W., VELKER, J., WELLER, T., XI, J.-F. & ZILTENER, P. (2004). Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362: 1-[2-(4-benzyl-4-hydroxy-piperidin-1- yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulphate salt): first demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther., 311, 204-212.
7. DOUGLAS, S.A. (2003). Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr. Opin. Pharmacol., 3, 159-167.
8. DOUGLAS, S.A., SULPIZIO, A.C., PIERCY, V., SARAU, H.M., AMES, R.S., AIYAR, N.V., OHLSTEIN, E.H. & WILLETTE, R.N. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol., 131, 1262-1274.
9. GARDINER, S.M., COMPTON, A.M. & BENNETT, T. (1990a). Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats. Br. J. Pharmacol., 99, 107-112.
10. GARDINER, S.M., COMPTON, A.M. & BENNETT, T. (1990b). Effect of indomethacin on the regional haemodynamic responses to low doses of endothelins and sarafotoxin. Br. J. Pharmacol., 100, 158-162.
11. GARDINER, S.M., MARCH, J.E., KEMP, P.A., DAVENPORT, A.P. & BENNETT, T. (2001). Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol., 132, 1625-1629.
12. GARDINER, S.M., MARCH, J.E., KEMP, P.A. & BENNETT, T. (2004). Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br. J. Pharmacol., 143, 422-430.
13. HASSAN, G.S., CHOUIALI, F., SAITO, T., HU, F., DOUGLAS, S.A., AO, Z., AO, Z., WILLETTE, R.N., OHLSTEIN, E.H. & GIAID, A. (2003). Effect of human urotensin-II infusion on haemodynamics and cardiac function. Can. J. Physiol. Pharmacol., 81, 125-128.
14. KOMPA, A.R., THOMAS, W.G., SEE, F., TZANIDIS, A., HANNAN, R.D. & KRUM, H. (2004). Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides, 25, 1783-1788.
15. KUC, R.E. (2002). Immunocytochemical localisation of endothelin peptides, precursors, and endothelin-converting enzymes. Methods Mol. Biol., 206, 3-19.
16. MAGUIRE, J.J. & DAVENPORT, A.P. (2002). Is urotensin-II the new endothelin? Br. J. Pharmacol., 137, 579-588.
17. QI, J.S., MINOR, L.K., SMITH, C., HU, B., YANG, J., ANDRADE-GORDON, P. & DAMIANO, B. (2005). Characterisation of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides, 26, 683-690.
18. RUSSELL, F.D., MOLENAAR, P. & O-BRIEN, D.M. (2001). Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol., 132, 5-9.
19. STAMLER, J.S. & MEISSNER, G. (2001). Physiology of nitric oxide in skeletal muscle. Physiol. Rev., 81, 209-237.
20. THANASSOULIS, G., HUYHN, T. & GIAID, A. (2004). Urotensin II and cardiovascular diseases. Peptides, 25, 1789-1794.
21. THEODORSSON-NORHEIM, E. (1987). Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput. Biol. Med., 17, 85-99.
22. WAKEFIELD, I.D., MARCH, J.E., KEMP, P.A., VALENTIN, J.-P., BENNETT, T. & GARDINER, S.M. (2003). Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br. J. Pharmacol., 139, 1235-1243.
23. WATSON, A.M.D., LAMBERT, G.W., SMITH, K.J. & MAY, C.N. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension, 42, 373-379.
24. WOOLARD, J., BENNETT, T., DUNN, W.R., HEAL, D.J., ASPLEY, S. & GARDINER, S.M. (2004). Acute cardiovascular effects of sibutramine in conscious rats. J. Pharmacol. Exp. Ther., 308, 1102-1110.
25. 1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats. Eur. J. Pharmacol., 419, 183-189.
26. ZHU, Y.Z., WANG, Z.J., ZHU, Y.C., ZHANG, L., OAKLEY, R.M.E., CHUNG, C.W., LIM, K.W., LEE, H.S., OZOUX, M.L., LINZ, W., BÕHM, M & KOSTENIS, E. (2004). Urotensin II causes fatal circulatory collapse in anesthetised monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am. J. Physiol., 286, H830-H836.